Nutraceutical News and Research

RSS

Nutraceutical, a portmanteau the words “nutrition” and “pharmaceutical”, is a food or food product that provides health and medical benefits, including the prevention and treatment of disease.

Insilico Medicine to introduce 'Cure a disease in a year' program at Biodata World Congress 2018

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery and real world evidence pipeline utilizing the next generation artificial intelligence, will present its research and introduce the "Cure a disease in a year" program at the World's leading congress for big data in precision medicine - Biodata World Congress 2018.

19 Nov 2018

Insilico Medicine to present latest advances in drug development at Supply Side West Conference

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in modern drug development at the Supply Side West Conference in Las Vegas, 8-9 of November.

2 Nov 2018

Insilico to present its research in AI for drug discovery at BioCentury China HealthCare Summit

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its research in AI for drug discovery at BioCentury China HealthCare Summit in Shanghai, 13-14 of November.

31 Oct 2018

Insilico to present latest research on biomarkers at Investing in the Age of Longevity Conference

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in human aging biomarker development at the Investing in the Age of Longevity Conference in London, 1 of November.

30 Oct 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Insilico to present advances in artificial intelligence at the Healthcare Innovation Summit Africa 2018

Insilico Medicine, a Rockville-based leader in next-generation artificial intelligence for drug discovery, biomarker development, and aging research, is pleased to announce the talk of its Head of Africa Artificial Intelligence for Healthcare Initiative, Iraneus Ogu, who will present alongside other academic thought leaders and industry experts at the 4th Healthcare Innovation Summit Africa 2018, one of the largest healthcare events in Africa.

12 Oct 2018

Top journal publishes special issue on deep learning for drug discovery and biomarker development

While the many concepts in artificial intelligence date back to the 20th century, the revolution in deep learning started around 2014-2015 when AI systems started outperforming humans in many tasks ranging from video games and image recognition to autonomous driving.

11 Oct 2018

Diet and weight may influence response to bipolar disorder treatment, shows study

Data from a clinical trial has shown that how people respond to treatment for Bipolar Disorder may be influenced by their weight and the overall quality of their diet, including whether they are eating a diet high in foods thought to contribute to general inflammation.

8 Oct 2018

Insilico Medicine collaborates with MAWI to develop multi-modal biomarkers of aging

Cardiovascular disease is the leading cause of death and disability in the world. On the eve of the annual World Heart Day, September 29th, Insilico Medicine, Inc., a Rockville-based next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research announced a research collaboration agreement with MAWI, the next-generation consumer and clinical wearable company, the developer of one of the most accurate clinical-grade ECG wearable devices.

28 Sep 2018

New research on molecular mechanistic understanding of drug delivery and drug delivery systems

Today, Insilico Medicine, Inc., a Rockville-based next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research announces the publication of a new research paper "Entangled Conditional Adversarial Autoencoder for de-novo Drug Discovery" in Molecular Pharmaceutics, the leading American Chemical Society journal covering research on the molecular mechanistic understanding of drug delivery and drug delivery systems

12 Sep 2018

UniSA researchers unearth potential cure for obesity

It costs the global economy an estimated US$2 trillion annually and has been dubbed a modern day health epidemic, but new research from the University of South Australia has unearthed a possible cure for obesity – and it is as plain as dirt!

31 Aug 2018

Insilico announces presentation of latest research at Global Precision Medicine & Biomarkers Leaders Summit

Insilico Medicine, a Rockville-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CTO, Alex Zhebrak at the 5th Global Precision Medicine & Biomarkers Leaders Summit, September 13-14, 2018, Munich, Germany.

27 Aug 2018

Scientists examine effects of consuming high-protein milk at breakfast on blood glucose levels, satiety

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas Goff, PhD, and the team of scientists from the Human Nutraceutical Research Unit at the University of Guelph, in collaboration with the University of Toronto, examined the effects of consuming high-protein milk at breakfast on blood glucose levels and satiety after breakfast and after a second meal.

20 Aug 2018

Silencing of GULP1 gene expression plays important role in ovarian carcinogenesis

Johns Hopkins researchers in collaboration with Insilico Medicine, a biotechnology company based in Rockville Maryland, identify that silencing of the GULP1 gene expression by methylation plays an important role in ovarian carcinogenesis.

7 Aug 2018

Otsuka’s JINARC approved for treatment of patients with CKD stage 4 ADPKD

Otsuka Pharmaceutical Europe Ltd. today announced that the European Commission has approved an extension of indication for JINARC to include adult patients with CKD stage 4 Autosomal Dominant Polycystic Kidney Disease

2 Aug 2018

Top AI companies join hands to discover novel drugs for DMD

Insilico Medicine a leader in artificial intelligence for drug discovery, biomarker development and aging research, announced a research collaboration agreement with A2A Pharmaceuticals, Inc. A2A is a biotechnology company headquartered in New York and focused on development of novel drugs for unmet needs in oncology, drug resistant bacterial infections, and other life threatening diseases.

20 Jul 2018

Outsiders swoop in vowing to rescue rural hospitals short on hope — and money

Beau Gertz faced a crowd of worried locals at this town's senior center, hoping to sell them on his vision for their long-beloved — but now bankrupt — hospital.

4 Jun 2018

New model based on combination of GANs with reinforcement learning for drug discovery

Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research announces the publication of a new research paper in Molecular Pharmaceutics journal titled "Adversarial Threshold Neural Computer for Molecular De Novo Design".

10 May 2018

Insilico’s CEO to deliver presentation on “Artificial Intelligence for Aging Research”

Insilico Medicine, a Baltimore-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CEO, Alex Zhavoronkov, at the Pioneers 18 Conference, May 25, 2018, Vienna, Austria.

28 Apr 2018

Insilico to present recent advances in AI for aging biomarkers and age management research

Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, biomarker development and aging research, is pleased to announce the presentation of its Director of Drug Discovery, Dr. Ivan Ozerov, at the 24th Clinical Applications for Age Management Medicine Conference, April 27, 2018, organized by Age Management Medicine Group.

6 Apr 2018